ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 9 (3) 171-182    DOI: 10.1677/erc.0.0090171
Copyright © 2002 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fruehauf, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fruehauf, J.
Endocrine Related Cancer, Vol 9, Issue 3, 171-182
Copyright © 2002 by Society for Endocrinology

Articles

In vitro assay-assisted treatment selection for women with breast or ovarian cancer

JP Fruehauf


The selection of chemotherapy for women with breast or ovarian carcinoma has been traditionally based on results from phase III comparative trials that define the most active drugs and drug combinations. This approach has led to a significant prolongation of the lives of these patients. Unfortunately, few patients with advanced stage IV disease are cured using the currently available regimens. In order to improve the selection process for individual patients, various types of in vitro tests that assess the activity of standard drugs on a patient's tumor have been developed over the past five decades. As with bacterial culture and sensitivity tests, significant predictive correlations between in vitro drug-response assays and cancer patient response and survival have been demonstrated. Medicare currently covers in vitro drug-resistance assays. This review discusses the historical development of in vitro drug-response assays and the clinical validation of various technologies currently available to assist the clinician in selecting the optimal therapy for each patient.


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
A. Quartino, M. O. Karlsson, A. Freijs, N. Jonsson, P. Nygren, J. Kristensen, E. Lindhagen, and R. Larsson
Modeling of In Vitro Drug Activity and Prediction of Clinical Outcome in Acute Myeloid Leukemia
J. Clin. Pharmacol., August 1, 2007; 47(8): 1014 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. A. d'Amato, R. J. Landreneau, W. Ricketts, W. Huang, R. Parker, E. Mechetner, I.-R. Yu, and J. D. Luketich
Chemotherapy resistance and oncogene expression in non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 352 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Fruehauf, H. Brem, S. Brem, A. Sloan, G. Barger, W. Huang, and R. Parker
In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas
Clin. Cancer Res., August 1, 2006; 12(15): 4523 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Fruehauf and D. S. Alberts
In Vitro Drug Resistance Versus Chemosensitivity: Two Sides of Different Coins
J. Clin. Oncol., May 20, 2005; 23(15): 3641 - 3643.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.